PROSTATE CANCER: Intermittent ADT—tales from a 27-year odyssey

    loading  Checking for direct PDF access through Ovid

Abstract

Intermittent androgen deprivation can reduce treatment-related adverse effects in men with prostate cancer. Data from the recent SWOG-9346 trial show a nonsignificant improvement in median overall survival in patients treated with continuous therapy compared with intermittent therapy, but are these data likely to change clinical practice?

Related Topics

    loading  Loading Related Articles